KR101907535B1 - 소염제 2-옥소티아졸 및 2-옥소옥사졸 - Google Patents

소염제 2-옥소티아졸 및 2-옥소옥사졸 Download PDF

Info

Publication number
KR101907535B1
KR101907535B1 KR1020177008521A KR20177008521A KR101907535B1 KR 101907535 B1 KR101907535 B1 KR 101907535B1 KR 1020177008521 A KR1020177008521 A KR 1020177008521A KR 20177008521 A KR20177008521 A KR 20177008521A KR 101907535 B1 KR101907535 B1 KR 101907535B1
Authority
KR
South Korea
Prior art keywords
alkyl
group
formula
halo
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177008521A
Other languages
English (en)
Korean (ko)
Other versions
KR20170038941A (ko
Inventor
조지 코코토스
베리트 요한슨
빅토리아 마그리오티
마이클 차코스
Original Assignee
아벡신 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벡신 에이에스 filed Critical 아벡신 에이에스
Publication of KR20170038941A publication Critical patent/KR20170038941A/ko
Application granted granted Critical
Publication of KR101907535B1 publication Critical patent/KR101907535B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y10S514/825—
    • Y10S514/857—
    • Y10S514/863—

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177008521A 2009-10-02 2010-10-01 소염제 2-옥소티아졸 및 2-옥소옥사졸 Expired - Fee Related KR101907535B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24833809P 2009-10-02 2009-10-02
US61/248,338 2009-10-02
PCT/EP2010/064687 WO2011039365A1 (en) 2009-10-02 2010-10-01 Anti inflammatory 2-oxothiazoles and 2 -oxooxazoles

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127011173A Division KR20120089701A (ko) 2009-10-02 2010-10-01 소염제 2-옥소티아졸 및 2-옥소옥사졸

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187028820A Division KR101997163B1 (ko) 2009-10-02 2010-10-01 소염제 2-옥소티아졸 및 2-옥소옥사졸

Publications (2)

Publication Number Publication Date
KR20170038941A KR20170038941A (ko) 2017-04-07
KR101907535B1 true KR101907535B1 (ko) 2018-10-15

Family

ID=43221889

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177008521A Expired - Fee Related KR101907535B1 (ko) 2009-10-02 2010-10-01 소염제 2-옥소티아졸 및 2-옥소옥사졸
KR1020197018997A Withdrawn KR20190082985A (ko) 2009-10-02 2010-10-01 소염제 2-옥소티아졸 및 2-옥소옥사졸
KR1020187028820A Expired - Fee Related KR101997163B1 (ko) 2009-10-02 2010-10-01 소염제 2-옥소티아졸 및 2-옥소옥사졸
KR1020127011173A Ceased KR20120089701A (ko) 2009-10-02 2010-10-01 소염제 2-옥소티아졸 및 2-옥소옥사졸

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020197018997A Withdrawn KR20190082985A (ko) 2009-10-02 2010-10-01 소염제 2-옥소티아졸 및 2-옥소옥사졸
KR1020187028820A Expired - Fee Related KR101997163B1 (ko) 2009-10-02 2010-10-01 소염제 2-옥소티아졸 및 2-옥소옥사졸
KR1020127011173A Ceased KR20120089701A (ko) 2009-10-02 2010-10-01 소염제 2-옥소티아졸 및 2-옥소옥사졸

Country Status (11)

Country Link
US (2) US9597318B2 (enExample)
EP (2) EP3431084A1 (enExample)
JP (1) JP6012468B2 (enExample)
KR (4) KR101907535B1 (enExample)
CN (3) CN102647984B (enExample)
AU (1) AU2010302584B2 (enExample)
CA (1) CA2782797C (enExample)
DK (1) DK2482815T3 (enExample)
IN (1) IN2012DN02982A (enExample)
NO (1) NO2482815T3 (enExample)
WO (1) WO2011039365A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6012468B2 (ja) 2009-10-02 2016-10-25 アヴェクシン エーエス 抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
JP6371312B2 (ja) 2013-01-29 2018-08-08 アヴェクシン エーエス 坑炎症および抗腫瘍２−オキソチアゾール化合物ならびに２−オキソチオフェン化合物
GB201307331D0 (en) * 2013-04-23 2013-05-29 Norwegian Univ Sci & Tech Ntnu Compound
GB201409363D0 (en) 2014-05-27 2014-07-09 Avexxin As Skin cancer treatment
GB201413695D0 (en) * 2014-08-01 2014-09-17 Avexxin As Compound
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB2550363A (en) * 2016-05-16 2017-11-22 Avexxin As Compound
WO2018055062A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
JP2019532980A (ja) * 2016-11-04 2019-11-14 アヴェクシン エーエス 皮膚症状を治療するためのチアゾールおよび副腎皮質ステロイドを含む併用療法
JP2019532979A (ja) * 2016-11-04 2019-11-14 アヴェクシン エーエス 皮膚症状を治療するためのチアゾールおよびセコステロイドを含む併用療法
JP7169584B2 (ja) * 2018-01-30 2022-11-11 公立大学法人横浜市立大学 オーキシン生合成阻害活性を有する新規化合物、その製造方法及びその用途
GB201806663D0 (en) 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
EP3677259A1 (en) * 2019-01-07 2020-07-08 Mosaiques Diagnostics And Therapeutics AG Use of arachidonyl trifluoromethyl ketone
GB202117609D0 (en) 2021-12-06 2022-01-19 Coegin Pharma Ab 2-Oxothiazole compositions for treatment of T-cell acute lymphoblastic leukaemia
CN115028597B (zh) * 2022-04-29 2024-03-26 闽都创新实验室 一种tempo连续脱氢环化制备苯并恶唑类衍生物的方法和应用
WO2025125241A1 (en) 2023-12-15 2025-06-19 Coegin Pharma Ab Pharmaceutical composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034254A1 (en) * 1998-12-04 2000-06-15 Astrazeneca Ab Novel compounds

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894152A (en) * 1969-09-15 1975-07-08 Innothera Lab Sa Use of (thienyl-3)(3-N-morpholine-propy)ketone
FR2062868B1 (enExample) * 1969-09-15 1973-08-10 Innothera Lab Sa
DE2063901A1 (en) 1970-12-28 1972-07-20 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Phenylalkylaminoalkylthiazoles - as antiphlogistics
PH22520A (en) 1984-11-12 1988-10-17 Yamanouchi Pharma Co Ltd Heterocyclic compounds having 4-lover alkyl-3-hydroxy-2-lower alkyl phenoxy-lower alkylene-y-group, and process of producing them
US5177215A (en) 1984-11-12 1993-01-05 Yamanouchi Pharmaceutical Co., Ltd. Heterocyclic compounds and pharmaceutical use thereof
JPS62142168A (ja) 1985-10-16 1987-06-25 Mitsubishi Chem Ind Ltd チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤
ZA894913B (en) 1988-07-12 1990-03-28 Ici Pharma Heterocyclic compounds
US5272986A (en) 1991-05-13 1993-12-28 British Gas Plc Towing swivel for pipe inspection or other vehicle
TW263504B (enExample) 1991-10-03 1995-11-21 Pfizer
GB9211706D0 (en) 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5273986A (en) 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5268395A (en) 1992-10-13 1993-12-07 Martin Marietta Energy Systems, Inc. Microcellular carbon foam and method
JP3345476B2 (ja) * 1993-05-18 2002-11-18 株式会社東芝 有機非線形光学材料
US5569655A (en) * 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
WO1996003392A1 (en) 1994-07-27 1996-02-08 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5658909A (en) * 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
US6214994B1 (en) * 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
CN1063443C (zh) 1995-03-28 2001-03-21 日本脏器制药株式会社 新的苯并噻唑衍生物
AU5860396A (en) * 1995-05-19 1996-11-29 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
CA2224121A1 (en) * 1995-06-06 1996-12-12 Donna Kaye Wilson Stereoselective method for synthesizing dolaphenine
DE19638408A1 (de) * 1996-09-19 1998-03-26 Merckle Gmbh 1-Substituierte 3-Acyl-4,5-dimethylpyrrol-2-carbonsäuren und 3-Acylindol-2-carbonsäuren sowie ihre Derivate als Hemmstoffe der cytosolischen Phospholipase A¶2¶
WO1998032741A1 (en) * 1997-01-29 1998-07-30 Zeneca Limited Inhibitors of farnesyl protein transferase
EP0867437B1 (en) 1997-03-14 2002-11-13 Koninklijke Philips Electronics N.V. "Method of preparing a thiophene-containing or furan -containing conjugated compound and precursor compound used therein".
EP1140791A2 (en) * 1997-09-23 2001-10-10 Bristol-Myers Squibb Company Selective cpla 2 inhibitors
JPH11255700A (ja) 1998-03-12 1999-09-21 Taiho Ind Co Ltd アセチルアセトン系金属錯体及びその合成法、並びにそれを用いた有機多層型エレクトロルミネッセンス素子
WO2000009500A2 (en) 1998-08-11 2000-02-24 Nihon Bayer Agrochem K.K. Nematicidal pyrazoles
AU5880600A (en) 1999-06-25 2001-01-31 Merck & Co., Inc. 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
JP2001240593A (ja) * 1999-10-12 2001-09-04 Japan Tobacco Inc 高トリグリセリド血症治療薬及び抗肥満薬
US6462054B1 (en) * 2000-03-27 2002-10-08 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
HUP0302473A2 (hu) 2000-05-18 2003-11-28 Daiichi Pharmaceutical Co., Ltd. Új benzotiofénszármazékok
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US6734207B2 (en) * 2001-04-20 2004-05-11 Parker Hughes Institute Cytotoxic compounds
US7056917B2 (en) 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
WO2003051194A1 (en) 2001-12-18 2003-06-26 3Cpm Company Endoscopic measurement of myoelectrical activity from intra-abdominal organs
GB0202002D0 (en) * 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
BR0312957A (pt) * 2002-07-27 2005-06-14 Astrazeneca Ab Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
US6930391B2 (en) 2002-08-27 2005-08-16 Intel Corporation Method for alloy-electroplating group IB metals with refractory metals for interconnections
US7662971B2 (en) 2002-10-08 2010-02-16 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
EP1562574A1 (en) * 2002-11-07 2005-08-17 Astrazeneca AB 2-oxo-ethanesulfonamide derivates
AU2004274303B2 (en) 2003-09-18 2010-07-22 Tokuyama Corporation Chromene compound
AR045651A1 (es) 2003-09-19 2005-11-02 Solvay Pharm Bv Derivados de tiazol como moduladores del receptor de cannabinoide
JP4226438B2 (ja) 2003-10-23 2009-02-18 エヌ・ティ・ティ・コムウェア株式会社 パック装置およびセンステーブル装置、ならびに移動軌跡算出方法、移動軌跡算出プログラム、その記録媒体
US20050137243A1 (en) 2003-12-23 2005-06-23 Souers Andrew J. Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
JP2005343889A (ja) * 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
JP4925821B2 (ja) * 2004-05-17 2012-05-09 大塚製薬株式会社 チアゾール化合物及びその用途
US7178364B2 (en) 2004-07-22 2007-02-20 Shapiro Kristen M Personal adornment
WO2006016218A1 (en) * 2004-08-03 2006-02-16 Pfizer Japan Inc. Aryl or heteroaryl carbonyl derivatives derivatives useful as vanilloid receptor 1 (vr1) antagonists
WO2006057503A1 (en) * 2004-11-25 2006-06-01 Lg Life Sciences, Ltd. NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
EP1954137A4 (en) * 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
AU2007217813A1 (en) 2006-02-17 2007-08-30 The Scripps Research Institute Oxazole ketones as modulators of fatty acid amide hydrolase
WO2008013963A2 (en) * 2006-07-28 2008-01-31 University Of Connecticut Fatty acid amide hydrolase inhibitors
CA2678735A1 (en) 2007-02-26 2008-09-04 Santen Pharmaceutical Co., Ltd. Novel pyrrole derivative having ureido group and aminocarbonyl group as substituents
WO2008107335A1 (en) * 2007-03-05 2008-09-12 F. Hoffmann-La Roche Ag Aminoamides as orexin antagonists
CA2689148A1 (en) * 2007-05-31 2008-12-11 The Scripps Research Institute Tricyclic inhibitors of fatty acid amide hydrolase
JP6012468B2 (ja) 2009-10-02 2016-10-25 アヴェクシン エーエス 抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール
US20130231468A1 (en) 2010-11-22 2013-09-05 Takeshi Yamashita Rare earth metal complex
JP6371312B2 (ja) * 2013-01-29 2018-08-08 アヴェクシン エーエス 坑炎症および抗腫瘍２−オキソチアゾール化合物ならびに２−オキソチオフェン化合物
GB201413695D0 (en) * 2014-08-01 2014-09-17 Avexxin As Compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034254A1 (en) * 1998-12-04 2000-06-15 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20170166539A1 (en) 2017-06-15
KR20190082985A (ko) 2019-07-10
KR20180114228A (ko) 2018-10-17
EP3431084A1 (en) 2019-01-23
HK1210157A1 (en) 2016-04-15
CN103772312A (zh) 2014-05-07
EP2482815A1 (en) 2012-08-08
US20110136879A1 (en) 2011-06-09
CA2782797A1 (en) 2011-04-07
US9597318B2 (en) 2017-03-21
AU2010302584A1 (en) 2012-05-24
KR20170038941A (ko) 2017-04-07
CN104892542B (zh) 2018-01-26
NO2482815T3 (enExample) 2018-09-29
DK2482815T3 (en) 2018-06-06
WO2011039365A1 (en) 2011-04-07
HK1197551A1 (zh) 2015-01-23
EP2482815B1 (en) 2018-05-02
CN104892542A (zh) 2015-09-09
IN2012DN02982A (enExample) 2015-07-31
CN102647984B (zh) 2015-03-25
AU2010302584B2 (en) 2015-09-10
CA2782797C (en) 2018-08-07
JP2013506639A (ja) 2013-02-28
JP6012468B2 (ja) 2016-10-25
CN103772312B (zh) 2016-08-17
CN102647984A (zh) 2012-08-22
KR20120089701A (ko) 2012-08-13
KR101997163B1 (ko) 2019-07-08
US10370344B2 (en) 2019-08-06

Similar Documents

Publication Publication Date Title
KR101907535B1 (ko) 소염제 2-옥소티아졸 및 2-옥소옥사졸
JP5597542B2 (ja) Ｓｃｄ阻害薬としてのトリアゾール誘導体
CN107074840B (zh) 用于治疗炎性疾病和过度增殖性疾病的具有作为cPLA2抑制剂的活性的2-氧代噻唑化合物
AU2003282754A1 (en) Novel heterocyclic analogs of diphenylethylene compounds
JP2009535387A (ja) Ｐｉ３キナーゼ阻害剤としてのチアゾール誘導体
CN105102438A (zh) 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
US20150099800A1 (en) Novel lipase inhibitors, reporter substrates and uses thereof
AU2015268638B2 (en) Anti inflammatory 2-oxothiazoles and 2-oxooxazoles
CA2330558A1 (en) (2-acylaminothiazole-4-yl)acetic acid derivatives
RU2454402C2 (ru) Производные фенилуксусной кислоты, как ингибиторы цог-2 (циклооксигеназы-2)
HK1197551B (en) Anti inflammatory 2-oxothiazoles and 2-oxooxazoles
HK1210157B (en) Anti inflammatory 2-oxothiazoles and 2-oxooxazoles
WO2003004484A1 (en) Novel aliphatic compounds, synthesis method and method of using the same
JP2518497B2 (ja) 抗脂血剤
WO1992021666A1 (fr) Derives de thiazole antagonistes de recepteurs a l'angiotensine ii
AlMekhlafia et al. Synthesis of novel diflunisal carboxamide derivatives to enhance anti-inflammatory activity
JP2006298885A (ja) ナフタレンカルボン酸誘導体及びこれを含有する医薬組成物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A17-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241006

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241006

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241006